Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
Save for later
Press Releases
Donate Now
MJFF in the News Save for later

Press Releases

Browse current and past press releases from The Michael J. Fox Foundation.

 From
To
  • Default content image

    MJFF and The Kinetics Foundation Collaborate on Search for Parkinson's Biomarker

    NEW YORK – The Michael J. Fox Foundation for Parkinson’s Research today announced that it is partnering with The Kinetics Foundation to measure the impact of an innovative computer-based device,…
    Learn more Save for later
  • Default content image

    Joint Statement by Six Parkinson’s Disease Organizations Regarding Proposed Label Change for Azilect

    Joint Statement by Six Parkinson’s Disease Organizations Regarding Proposed Label Change for AzilectFDA Advisory Committee Meeting This statement is prepared on behalf of the American Parkinson…
    Learn more Save for later
  • Default content image

    MJFF Awards AFFiRiS $1.5 Million for the Clinical Development of the First Parkinson's Disease Vaccine

    NEW YORK, USA AND VIENNA, AUSTRIA–The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of…
    Learn more Save for later
  • Default content image

    MJFF Awardee Builds on Foundation Funding to Land $8 Million Follow-on Award from NINDS

    Last week, Banner Sun Health Research Institute (BSHRI) and Mayo Clinic Arizona announced an $8 million, five-year grant from The National Institute of Neurological Disorders and Stroke (NINDS) to…
    Learn more Save for later
  • Default content image

    Vanderbilt-MJFF Partnership Yields Drug-Like Molecules Aimed at Improving Treatment of Parkinson's Disease

    Researchers at Vanderbilt University Medical Center have achieved a milestone in the development of a potential new treatment for Parkinson’s disease that may improve on some of the limitations of…
    Learn more Save for later
  • Default content image

    Addex Moving Forward with Phase II Study to Reduce Levodopa-induced Dyskinesia

    Addex Pharmaceuticals is moving forward with a Phase IIa study evaluating the metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator, called dipraglurant (ADX48621), in reducing…
    Learn more Save for later
  • Default content image

    The Michael J. Fox Foundation Launches LRRK2 Cohort Consortium

    The Michael J. Fox Foundation (MJFF) launched the LRRK2 Cohort Consortium, a group of eight separate groups funded by MJFF to assemble and study groups of people with and without Parkinson’s disease …
    Learn more Save for later
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.